Nateglinide (Starlix)

A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.

Also Known As:

Starlix; A 4166; A-4166; AY 4166; AY-4166; DJN 608; Fastic; N-((4-Isopropylcyclohexyl)carbonyl)phenylalanine; Nate-Glinide; Nateglinide, (D-Phe)-isomer; Nateglinide, (cis,D-Phe)-isomer; Senaglinide; Starsis; A4166; AY4166; D-phenylalanine, N-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-

Networked: 242 relevant articles (41 outcomes, 95 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Califf, Robert M: 14 articles (10/2020 - 10/2008)
2.	Holman, Rury R: 14 articles (10/2020 - 10/2008)
3.	Haffner, Steven M: 12 articles (05/2017 - 10/2008)
4.	Sun, Jie-Lena: 10 articles (01/2018 - 01/2012)
5.	McMurray, John J V: 9 articles (01/2018 - 04/2010)
6.	Bethel, M Angelyn: 8 articles (01/2018 - 10/2008)
7.	Thomas, Laine: 8 articles (01/2018 - 03/2013)
8.	Hirose, Takahisa: 7 articles (07/2018 - 12/2002)
9.	Leiter, Lawrence A: 7 articles (12/2013 - 01/2005)
10.	Watada, Hirotaka: 6 articles (09/2015 - 08/2004)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 09/01/2000 - "In randomised, double-blind 24-week studies in patients with type 2 diabetes, oral nateglinide 120 mg 3 times daily before meals improved glycaemic control significantly relative to placebo. " 12/01/2021 - "Genetic polymorphisms in the MTNR1B gene is associated with type 2 diabetes mellitus (T2DM); however, there is no evidence about its impact on the therapeutic efficacy of nateglinide. " 12/01/2021 - "Evaluation of the effect of MTNR1B rs10830963 gene variant on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients." 11/12/2021 - "Genetic polymorphisms in the PPARD and NOS1AP is associated with type 2 diabetes mellitus (T2DM); however, there is no evidence about its impact on the therapeutic efficacy of nateglinide. " 11/12/2021 - "PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus."
2.	Hyperglycemia 09/01/2002 - "In sum, nateglinide is a safe and effective therapeutic option for treatment of patients with mild to moderate fasting hyperglycemia." 12/01/2002 - "Nateglinide was safe and effective in reducing postprandial hyperglycemia in subjects with IGT. " 05/01/2014 - "However, nateglinide pretreated i.c.v. did not affect the KA-induced neuronal cell death and hyperglycemia. " 03/01/2007 - "Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients." 01/01/2007 - "In prediabetic subjects with IGT, nateglinide restores early insulin secretion and reduces postprandial hyperglycemia. "
3.	Insulin Resistance 03/01/2006 - "Beneficial effects of nateglinide on insulin resistance in type 2 diabetes." 03/01/2006 - "Nateglinide ameliorates insulin resistance as well as insulin secretory defects in type 2 diabetic patients." 07/01/2007 - "This trial had shown that nateglinide and repaglinide could comparably improve insulin sensitivity and beta-cell function." 03/01/2006 - "The aim of this study is to evaluate the effect of nateglinide on insulin resistance as well as insulin secretory defects in type 2 diabetic patients. " 03/01/2005 - "The aim of this study was to investigate the influence of changes in insulin resistance and early insulin secretion on the insulin secretagogic effects of nateglinide. "
4.	Hypoglycemia (Reactive Hypoglycemia) 12/01/2013 - "One of the dangerous side effects of nateglinide administration is rapid hypoglycemia, a condition that needs to be monitored carefully to prevent unnecessary fatalities. " 04/22/2010 - "Nateglinide did, however, increase the risk of hypoglycemia. " 11/01/2005 - "Severe hypoglycemia was recognized in only 1 case of diabetes complicated by serious renal dysfunction, for which nateglinide has been contraindicated in Japan. " 01/01/2005 - "Hypoglycemia following a nateglinide overdose in a suicide attempt." 02/01/2004 - "Nateglinide was not associated with hypoglycemia or other adverse events. "
5.	Glucose Intolerance 12/01/2002 - "The purpose of this study was to evaluate the metabolic effectiveness, safety, and tolerability of nateglinide in subjects with impaired glucose tolerance (IGT) and to identify a dose appropriate for use in a diabetes prevention study. " 06/15/2010 - "Nateglinide did not reduce diabetes or CV events in patients with impaired glucose tolerance and CV risk factors." 02/01/2005 - "[Effects of nateglinide in impaired glucose tolerance subjects]." 10/01/2005 - "Nateglinide also restores early insulin secretion and reduces postprandial hyperglycaemia in prediabetic subjects with impaired glucose tolerance (IGT) and appears similarly effective in elderly and non-elderly populations with type 2 diabetes. " 02/01/2011 - "Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors."

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Glucose (Dextrose)
3.	Acarbose
4.	Metformin (Glucophage)
5.	voglibose (Basen)
6.	Hypoglycemic Agents (Hypoglycemics)
7.	Glyburide (Glibenclamide)
8.	repaglinide (Prandin)
9.	Blood Glucose (Blood Sugar)
10.	Thiazolidinediones

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Exercise Therapy (Therapy, Exercise)
4.	Intravenous Administration
5.	Oral Administration